| Name | Adefovir dipivoxil |
| Description | Adefovir dipivoxil (GS 0840) is a dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV). |
| In vitro | Compared to the placebo control group with 5.3 log10 GE/mL, Adefovir Dipivoxil significantly reduced serum HBV DNA levels in transgenic mice to 3.5 log10 genome equivalents (GE) per mL, indicating a marked suppression of the hepatitis B virus. In the liver, Adefovir Dipivoxil's antiviral activity peaked on day 10, achieving hepatitis B virus inhibition endpoints at a dose of 1.0 mg/kg/day. Furthermore, Adefovir Dipivoxil decreased liver HBV DNA to <0.1 picograms of hepatitis B virus per total DNA (picograms/mg) in each transgenic mouse. |
| In vivo | In the duck HBV (DHBV) model, Adefovir dipivoxil, when used in combination with other nucleoside analogs (Lamivudine, Entecavir, Emtricitabine [FTC], and Telbivudine [L-dT]), exhibits superior antiviral effects compared to monotherapy. Adefovir dipivoxil effectively inhibits viral CCC DNA both in vitro and in vivo within the same model. Notably, Adefovir retains significant anti-HBV activity soon after being introduced to cells. Its use in conjunction with Lamivudine, FTC, or L-dT demonstrates cumulative effects, while synergy is observed when combined with Entecavir or Tenofovir. Additionally, Adefovir dipivoxil suppresses the activity of the polymerase by inhibiting the transcription of the pre-genomic RNA. The dosage of Adefovir dipivoxil is correlated with its ability to suppress the release of the virus in culture supernatants and the synthesis of viral DNA within cells. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.58 mM), Sonication is recommended.
DMSO : 250 mg/mL (498.53 mM), Sonication is recommended.
Ethanol : 93 mg/mL (185.45 mM), Sonication is recommended.
|
| Keywords | ReverseTranscriptase | Reverse Transcriptase | Protein P | prodrug | oral | nucleotide | Inhibitor | inhibit | infection | Hepatitis B virus | HBV | GS-0840 | GS0840 | Endogenous Metabolite | analogue | Adefovir dipivoxil |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Malic acid | Formamide | Glycerol | Thymidine | Corn starch | Gluconate Calcium |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Chinese Pharmacopoeia Natural Product Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Heat-Clearing and Detoxifying Traditional Chinese Medicine Compound Library | Anti-Cancer Drug Library |
United States
